miR-375 inhibits cell growth and correlates with clinical outcomes in tongue squamous cell carcinoma

Jia,Lingfei; Huang,Yiping; Zheng,Yunfei; Lyu,Mingyue; Zhang,Chunan; Meng,Zhen; Gan,Yehua; Yu,Guangyan

doi:10.3892/or.2015.3759

miR-375 inhibits cell growth and correlates with clinical outcomes in tongue squamous cell carcinoma

Authors:
- Lingfei Jia
- Yiping Huang
- Yunfei Zheng
- Mingyue Lyu
- Chunan Zhang
- Zhen Meng
- Yehua Gan
- Guangyan Yu
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, P.R. China, Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing 100081, P.R. China
Published online on: January 28, 2015 https://doi.org/10.3892/or.2015.3759
Pages: 2061-2071

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

miR-375 has been implicated in various types of cancers. However, its role in tongue squamous cell carcinoma (TSCC) remains unclear. This study aimed to investigate the effects of miR-375 on cell growth and the prognosis of TSCC patients. Using quantitative reverse transcription-polymerase chain reaction, we evaluated miR-375 expression in TSCC samples and TSCC cell lines. The results showed that miR-375 expression was significantly reduced in the TSCC tissues and cell lines. A low level expression of miR-375 in TSCC patients was related to poor of prognosis. Moreover, the effects of miR-375 overexpression on cell proliferation, the cell cycle and the expression of Sp1 and cyclin D1 were examined in TSCC cells. We demonstrated that overexpression of miR-375 significantly inhibited the cell proliferation and cell cycle progression in TSCC cell lines. Overexpression of miR-375 inhibited Sp1 expression by targeting the 3' untranslated region of the Sp1 transcript. The knockdown of Sp1 expression resulted in the subsequent downregulation of cyclin D1. Taken together, our study suggests that miR-375 inhibits the cell growth, and its expression is correlated with clinical outcomes in TSCC.

View Figures

View References

1	Leemans CR, Braakhuis BJ and Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer. 11:9–22. 2011. View Article : Google Scholar
2	Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001. View Article : Google Scholar : PubMed/NCBI
3	Patel SG and Shah JP: TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin. 55:242–258. 2005. View Article : Google Scholar : PubMed/NCBI
4	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
5	Shah NG, Trivedi TI, Tankshali RA, et al: Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck. 31:1544–1556. 2009. View Article : Google Scholar : PubMed/NCBI
6	Inui M, Martello G and Piccolo S: MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bartels CL and Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009. View Article : Google Scholar : PubMed/NCBI
8	Jia LF, Wei SB, Gong K, Gan YH and Yu GY: Prognostic implications of micoRNA miR-195 expression in human tongue squamous cell carcinoma. PLoS One. 8:e566342013. View Article : Google Scholar : PubMed/NCBI
9	Li J, Huang H, Sun L, et al: MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 15:3998–4008. 2009. View Article : Google Scholar : PubMed/NCBI
10	Sun L, Yao Y, Liu B, et al: MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 31:432–445. 2012. View Article : Google Scholar
11	Siow M, Ng LK, Chong VV, et al: Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis. 20:345–351. 2014. View Article : Google Scholar
12	Harris T, Jimenez L, Kawachi N, et al: Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol. 180:917–928. 2012. View Article : Google Scholar : PubMed/NCBI
13	Bell RB, Kademani D, Homer L, Dierks EJ and Potter BE: Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity. J Oral Maxillofac Surg. 65:229–236. 2007. View Article : Google Scholar : PubMed/NCBI
14	Shaw RJ, McGlashan G, Woolgar JA, et al: Prognostic importance of site in squamous cell carcinoma of the buccal mucosa. Br J Oral Maxillofac Surg. 47:356–359. 2009. View Article : Google Scholar
15	Ding L, Xu Y, Zhang W, et al: MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 20:784–793. 2010. View Article : Google Scholar : PubMed/NCBI
16	Zhou J, Song S, He S, et al: MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway. Int J Mol Med. 33:950–956. 2014.PubMed/NCBI
17	Kong KL, Kwong DL, Chan TH, et al: MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 61:33–42. 2012. View Article : Google Scholar
18	Zhao H, Zhu L, Jin Y, Ji H, Yan X and Zhu X: miR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells. Acta Biochim Biophys Sin. 44:177–182. 2012. View Article : Google Scholar
19	Wang F, Li Y, Zhou J, et al: miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol. 179:2580–2588. 2011. View Article : Google Scholar : PubMed/NCBI
20	Nagata D, Suzuki E, Nishimatsu H, et al: Transcriptional activation of the cyclin D1 gene is mediated by multiple cis-elements, including SP1 sites and a cAMP-responsive element in vascular endothelial cells. J Biol Chem. 276:662–669. 2001. View Article : Google Scholar
21	Grinstein E, Jundt F, Weinert I, Wernet P and Royer HD: Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene. 21:1485–1492. 2002. View Article : Google Scholar : PubMed/NCBI
22	Lu Y, Thomson JM, Wong HY, Hammond SM and Hogan BL: Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol. 310:442–453. 2007. View Article : Google Scholar : PubMed/NCBI
23	Jia LF, Wei SB, Gan YH, et al: Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma. Int J Cancer. 135:2282–2293. 2014. View Article : Google Scholar
24	Zhang WH, Gui JH, Wang CZ, et al: The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncol Res. 20:139–147. 2012. View Article : Google Scholar : PubMed/NCBI
25	Li J, Li X, Li Y, et al: Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One. 8:e535822013. View Article : Google Scholar : PubMed/NCBI
26	Li Y, Jiang Q, Xia N, Yang H and Hu C: Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res. 40:1662–1669. 2012. View Article : Google Scholar : PubMed/NCBI
27	Yu H, Jiang L, Sun C, et al: Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 534:60–65. 2014. View Article : Google Scholar : PubMed/NCBI
28	Chang C, Shi H, Wang C, et al: Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett. 531:204–208. 2012. View Article : Google Scholar : PubMed/NCBI
29	Wang Z, Hong Z, Gao F and Feng W: Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia. Mol Cell Biochem. 383:59–65. 2013. View Article : Google Scholar : PubMed/NCBI
30	Li H, Shang H, Shu D, et al: gga-miR-375 plays a key role in tumorigenesis post subgroup J avian leukosis virus infection. PLoS One. 9:e908782014. View Article : Google Scholar : PubMed/NCBI
31	Wang Y, Tang Q, Li M, Jiang S and Wang X: MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. Biochem Biophys Res Commun. 444:199–204. 2014. View Article : Google Scholar : PubMed/NCBI
32	Cawley S, Bekiranov S, Ng HH, et al: Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell. 116:499–509. 2004. View Article : Google Scholar : PubMed/NCBI
33	Michinaga S, Ishida A, Takeuchi R and Koyama Y: Endothelin-1 stimulates cyclin D1 expression in rat cultured astrocytes via activation of Sp1. Neurochem Int. 63:25–34. 2013. View Article : Google Scholar : PubMed/NCBI
34	Cram EJ, Liu BD, Bjeldanes LF and Firestone GL: Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J Biol Chem. 276:22332–22340. 2001. View Article : Google Scholar : PubMed/NCBI
35	Baldin V, Lukas J, Marcote MJ, Pagano M and Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
36	Motokura T, Keyomarsi K, Kronenberg HM and Arnold A: Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J Biol Chem. 267:20412–20415. 1992.PubMed/NCBI
37	Bova RJ, Quinn DI, Nankervis JS, et al: Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res. 5:2810–2819. 1999.PubMed/NCBI
38	Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E and Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 55:975–978. 1995.PubMed/NCBI
39	Huang SF, Cheng SD, Chuang WY, et al: Cyclin D1 overexpression and poor clinical outcomes in Taiwanese oral cavity squamous cell carcinoma. World J Surg Oncol. 10:402012. View Article : Google Scholar : PubMed/NCBI
40	Chang YC, Illenye S and Heintz NH: Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene. Mol Cell Biol. 21:1121–1131. 2001. View Article : Google Scholar : PubMed/NCBI
41	Kim SJ, Onwuta US, Lee YI, Li R, Botchan MR and Robbins PD: The retinoblastoma gene product regulates Sp1-mediated transcription. Mol Cell Biol. 12:2455–2463. 1992.PubMed/NCBI
42	Datta PK, Raychaudhuri P and Bagchi S: Association of p107 with Sp1: genetically separable regions of p107 are involved in regulation of E2F- and Sp1-dependent transcription. Mol Cell Biol. 15:5444–5452. 1995.PubMed/NCBI
43	Karlseder J, Rotheneder H and Wintersberger E: Interaction of Sp1 with the growth- and cell cycle-regulated transcription factor E2F. Mol Cell Biol. 16:1659–1667. 1996.PubMed/NCBI
44	Gualberto A and Baldwin AS Jr: p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem. 270:19680–19683. 1995. View Article : Google Scholar : PubMed/NCBI
45	Johnson-Pais T, Degnin C and Thayer MJ: pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc Natl Acad Sci USA. 98:2211–2216. 2001. View Article : Google Scholar : PubMed/NCBI